June 30th, 2020, 11am EDT

Even as governments around the world begin to re-open, COVID-19 will have a lasting impact on how the pharmaceutical industry functions both in the immediate future and long-term. The development, trial and manufacture of medications will drastically change as sponsors find new ways to interact with both contract manufacturing organizations and patients. How can you navigate this unprecedented environment while still meeting milestones? Join Thermo Fisher Scientific’s drug development and manufacturing experts for a unique, extended Q&A session and learn how to start navigating the new normal.

Key Learning Objectives: 

• The impact of COVID-19 on sponsor/CDMO relationships moving forward
• How Thermo Fisher Scientific has maintained normal CDMO operations and plans to shift to meet new needs
• Answers to your questions surrounding the new post-pandemic landscape

This is a webinar series, part 2 in this series will cover Post-Pandemic Planning: What Will Change in the Clinical Supply Chain?
Click here for details

Christy Eatmon

Global SME
Sterile Drug Products
View Biography

Michael P. Cruskie Jr., PhD,

Senior Director and General Manager
API
View Biography

Jeff Hou

Senior Manager, Scientific and Technical Affairs
Thermo Fisher Scientific
View Biography

Kevin Kane, PhD

Global SME

View Biography